

were retested in duplicate to rule out the presence of PCR inhibitors. Three of them were then found to have no inhibitors, while one had presence of PCR inhibitors.

**Conclusions** Our results show that although majority of cases studied were due to HSV-2, HSV-1 either alone or as a mixed infection with HSV-2 is not uncommon. PCR was found to be as sensitive as DFA for confirming the syndromic diagnosis, but some false negatives may occur due to presence of PCR inhibitors.

**Abstract P5.080 Table 1**

HSV1 DFA			
HSV1 PCR	Positive	Negative	Total
Positive	10	1	11
Negative	1	32	33
Total	11	33	44

**Abstract P5.080 Table 2**

HSV2 DFA			
HSV2 PCR	Positive	Negative	Total
Positive	21	3	24
Negative	5	15	20
Total	26	18	44

**P5.081 ANALYTICAL EVALUATION OF THE GENEXPERT® CT/NG, THE FIRST GENETIC POINT OF CARE ASSAY FOR SIMULTANEOUS DETECTION OF NEISSERIA GONORRHOEAEE AND CHLAMYDIA TRACHOMATIS**

doi:10.1136/sextrans-2013-051184.1125

<sup>1,2</sup>S N Tabrizi, <sup>3</sup>M Unemo, <sup>4</sup>D Golparian, <sup>5</sup>J Twin, <sup>6</sup>A E Limnios, <sup>6</sup>M Lahra, <sup>7</sup>R Guy, on behalf of TTANGO Investigators. <sup>1</sup>Department of Microbiology and Infectious Diseases, The Royal Women's Hospital, Parkville, Australia; <sup>2</sup>Department of Obstetrics and Gynaecology, University of Melbourne, The Royal Women's Hospital and Murdoch Childrens Research Institute, Parkville, Australia; <sup>3</sup>WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden; <sup>4</sup>WHO Collaborating Centre for Gonorrhoea and other STIs, Department of Laboratory Medicine, Microbiology, Örebro University Hospital, Örebro, Sweden; <sup>5</sup>The Royal Women's Hospital, Parkville, Australia; <sup>6</sup>4) WHO Collaborating Centre for STD, Microbiology Department, The Prince of UK Hospital, Randwick, Australia; <sup>7</sup>Kirby Institute, University of NSW, Sydney, Australia

**Introduction** New assays for molecular detection of *Neisseria gonorrhoeae* and *Chlamydia trachomatis* need to be evaluated for potential false positive and false negative results due to cross reaction with other species, and potential mutations and genetic exchanges with other closely related organisms. Cepheid GeneXpert® CT/NG is the first FDA approved genetic point of care (POC) assay which simultaneously detects *C. trachomatis*, *N. gonorrhoeae* and controls for sample adequacy, in less than 90 minutes.

**Method** This study evaluated the GeneXpert® CT/NG assay with 372 characterised culture isolates; 111 *N. gonorrhoeae* isolates (including 3 isolates with *N. meningitidis porA* sequence), 223 isolates of non-gonococcal *Neisseria* species, 13 isolates of other species closely related to *Neisseria* and 25 *C. trachomatis* strains of different serovars (including LGV and nvCT strains).

**Results** All *C. trachomatis* and *N. gonorrhoeae* isolates were detected. A detection sensitivity of 10 genome copies per reaction was obtained with all *C. trachomatis* serovars as well as a representative *N. gonorrhoeae* control strain. Among the 223 non-gonococcal isolates, 4/11 *N. mucosa* and 2/42 *N. subflava* isolates were positive in one of the two *N. gonorrhoeae* targets (NG4), however

the assay flagged all 6 as negative due to requirements of both NG targets being positive for the assay to display an *N. gonorrhoeae* positive result.

**Conclusion** GeneXpert® CT/NG assay was analytically highly sensitive and specific for detection of *C. trachomatis* and *N. gonorrhoeae*, showing great promise as a POC assay. Detection of two NG targets is highly advantageous for avoiding false positive *N. gonorrhoeae* results.

**P5.082 WHAT ARE THE COSTS AND BENEFITS OF IMPLEMENTING POINT OF CARE TESTS FOR CHLAMYDIA TRACHOMATIS AND NEISSERIA GONORRHOEAEE IN GENITOURINARY MEDICINE CLINICS?**

doi:10.1136/sextrans-2013-051184.1126

<sup>1</sup>K M Turner, <sup>2</sup>J Round, <sup>3</sup>A Deol, <sup>1</sup>P Horner, <sup>1</sup>J Macleod, <sup>4</sup>S Goldenberg, <sup>5</sup>E Adams. <sup>1</sup>University of Bristol, Bristol, UK; <sup>2</sup>University College London, London, UK; <sup>3</sup>Aquarius Population Health, London, UK; <sup>4</sup>Guy's & St. Thomas' NHS Foundation Trust and King's College London, London, UK

**Background** To estimate the costs and benefits of new patient pathways in genitourinary medicine (GUM) clinics that incorporate a point of care (POC) nucleic acid amplification test (NAAT) for chlamydia and gonorrhoea (CT/NG), compared to standard off-site laboratory testing.

**Method** We modelled 20,000 GUM clinic attendees, based on GUMCAD reported diagnoses for men and women in England (2011). A Markov model with Monte Carlo simulation in Excel was developed. We compared existing standard pathways of testing and treatment using a CT/NG test with a new POC NAAT. Scenario and sensitivity analyses were conducted to evaluate the robustness of the model findings. The primary outcome was incremental cost effectiveness ratio (ICER, £ per QALY) of testing and treatment in GUM clinics. Secondary outcomes included the number of over-treatments for CT/NG, complications and transmissions averted, and change in time from test to treatment.

**Results** The total cost of using the CT/NG POC NAAT in 20,000 patients was £1.73 million and £1.92 million for standard care. The new POC NAAT pathway dominated (less expensive and increased QALYs, ICER of £4,397/QALY saved). As many as 541 unnecessary treatments could be prevented using POC NAAT. The shorter time to treatment for patients receiving same-day diagnosis and treatment may also prevent a small number of complications (3.4 cases PID) and onward transmissions (31.9 infections).

**Discussion** Replacing standard laboratory tests for CT/NG with a POC NAAT seems to be cost saving or at least cost neutral, and patients would benefit from more accurate diagnosis and less unnecessary treatment. POC NAATs would effectively eliminate the need for presumptive treatment.

**P5.083 WHAT QUALITIES DO PROVIDERS IDENTIFY AS BEST FOR POINT OF CARE STI TESTS AND DO OPINIONS DIFFER BY PRACTISE, REGION AND COUNTRY?**

doi:10.1136/sextrans-2013-051184.1127

<sup>1</sup>A M Rompalo, <sup>1</sup>Y Hsieh, <sup>2</sup>R Guy, <sup>2</sup>L Natoli, <sup>3</sup>C Fairley, <sup>4</sup>S Gupta, <sup>5</sup>K Radcliffe, <sup>1</sup>M T Hogan, <sup>1</sup>M J Goheen, <sup>1</sup>C Gaydos. <sup>1</sup>Johns Hopkins School of Medicine, Baltimore, MD, United States; <sup>2</sup>The Kirby Institute University of New South UK, Coogee, Australia; <sup>3</sup>University of Melbourne, Carlton, Australia; <sup>4</sup>All India Institute of Medical Sciences, New Delhi, India; <sup>5</sup>University Hospitals Birmingham, Birmingham, UK

**Background** U.S. clinicians identified high sensitivity and low cost as the most desirable characteristics for a Sexually Transmitted Infection (STI) Point Of Care Test (POCT); indicated performance time as major barrier; and chose Chlamydia trachomatis as the first choice for POCT development. We determined if POCT priorities, preferred qualities and barriers were similar for practitioners globally.

**Methods** An online survey was designed based on a large-scale in depth focus discussion study among STI experts and professionals and distributed via email to current IUSTI members. Conditional logistical regression modelling will be used for data analysis. We present preliminary data here.

**Results** To date, 142 subjects took the online survey with 123 completing it: 44% (n = 63) male and 56% (n = 79) female. Most subjects were from Oceania (35%) followed by Europe (18%), America (18%), Africa (15%) and Asia (14%). The majority (59%) of participants were from developed countries. Unreliability (17%) was the greatest barrier for use of POCTs, followed by being laboratory-driven (15%) and time-frame (13%). Perceptions of STI POCT differed significantly between developing and developed country participants. The majority (85%) of participants from developing countries thought test cost was more important versus 67% from developed countries ( $p < 0.05$ ). Participants from developing countries ranked early HIV seroconversion as top priority for new STI POCT while those from developed countries chose chlamydia. Only 24% from developing countries preferred to prioritise the development of chlamydia POCT as compared to 57% from developed countries. (p value?) In addition, the majority (53%) of participants from developed countries preferred a POCT with higher sensitivity but longer turn-around-time and much more expensive but only 28% from developing countries preferred this POCT ( $p < 0.05$ ).

**Conclusion** One STI POCT may not fit all. Industry should consider country identified needs in development of future acceptable, usable STI POCT.

**P5.084 MULTIPLEX CAPABILITY OF A FULLY-INTEGRATED, LOW-COST, ULTRA-RAPID PCR DEVICE WITH POINT-OF-CARE APPLICATIONS**

doi:10.1136/sextrans-2013-051184.1128

D Pearce, B Marsh. *Atlas, Trowbridge, UK*

**Background** We have developed a novel Point-of-Care molecular assay system, io™, comprising an assay-specific Cartridge and Reader. With a turnaround time of just 30 minutes the System has an initial focus on rapidly detecting sexually-transmitted infections (STIs). The System has been developed to run tests that simultaneously detect *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (NG), each run with an internal control (IC). The assays utilise a novel electrochemical method that demonstrates low copy number amplification and detection. Here, we have developed a CT/NG/IC triplex assay where each target analyte is co-amplified prior to being differentially detected.

**Methods** The assays were run using prototype PCR Cartridges in conjunction with an ultra-rapid thermocycler. All reagents necessary to perform the assay were deposited into the Cartridge. A sample was added to the Cartridge, DNA extracted, and the resulting eluate reconstituted dried amplification reagents. Amplified targets were detected using electrochemically-labelled target-specific probes and a double-stranded DNA-specific nuclease to release the electrochemical labels. Released labels were detected by applying a voltage to a screen-printed carbon electrode. Measurable current at specific oxidation potentials indicated the presence of targets in the sample.

**Results** Initial analytical sensitivity of the triplex CT/NG/IC assay was evaluated by testing each target analyte in combination with various concentrations of the other two (including negative controls). Electrochemical detection demonstrated clear differentiation between peaks generated by each cleaved label and showed a limit of detection of ten genome copies. Negative samples showed no significant peaks.

**Conclusions** The results showed that reliable, differentiated detection of three targets in a single sample was possible across a wide range of concentrations of the three targets. While demonstrated here for three analytes, the Atlas high-multiplex technology

will allow expansion of the Atlas io™ test menu to detect multiple STIs in a single sample.

**P5.085 TREPONEMA PALLIDUM ANTIBODIES DETECTION BY A POINT-OF-CARE TEST AND RPR AND TPHA TESTS IN MSM ATTENDING A COMMUNITY BASED HIV ANONYMOUS CENTER - CHECKPOINT LX**

doi:10.1136/sextrans-2013-051184.1129

<sup>1</sup>R Castro, <sup>1</sup>Â Lopes, <sup>3</sup>R Fuertes, <sup>3</sup>H Machado, <sup>3</sup>M Rocha, <sup>3</sup>R Jordão, <sup>3</sup>J Brito, <sup>3</sup>J Esteves, <sup>3</sup>M J Campos, <sup>1</sup>F Pereira. <sup>1</sup>Instituto de Higiene e Medicina tropical, Lisboa, Portugal; <sup>2</sup>Centro de Recursos Microbiológicos-CREM, Lisboa, Portugal; <sup>3</sup>CheckpointLX, Lisboa, Portugal

**Background** When available, point-of-care tests are very useful in the screening of STIs. They have affordable prices, need minimal equipment and training, results are immediately available, allowing treatment with no delay.

**Objectives** We describe the prevalence of syphilis in an MSM population attending an HIV Anonymous Testing Center (ATC), who stated that they were never infected with *Treponema pallidum*, as evaluated with a rapid test. Positive results were confirmed with the RPR and TPHA tests.

**Materials and Methods** Nine hundred and forty four individuals attending the HIV ATC were tested with the Determine Syphilis TP test. Those who were found to have reactive results had blood taken for confirmation with RPR and TPHA tests.

**Results** The rapid test was reactive in 44 of the 944 (4.7%) individuals. Samples were further tested with the RPR and the TPHA tests; 34 showed to have antibodies against *T. pallidum* in both tests, although one sample was reactive only at the 1:2 dilution in the RPR and its TPHA titer was 1:640. Six samples were only reactive for the TPHA test, while four were non reactive in both tests. The FTA-ABS was performed in these four samples and it was non reactive.

**Discussion and conclusion:** In accordance with the results of the rapid test, the percentage of reactive samples was 4.7% (44/944). However, when confirmatory tests were performed in the samples received in the laboratory, the percentage of reactive samples decreased to 4.2% (40/944). Furthermore, in six of these samples only the TPHA was reactive, meaning that these patients probably had a treated past infection, which was not detected as such by the rapid test.

In conclusion, the Determine Syphilis TP test seems to be useful as a screening test for syphilis, although it does not differentiate between treated and active syphilis.

**P5.086 DIAGNOSIS OF EXTRA-GENITAL CHLAMYDIA AND/OR GONORRHOEA INFECTIONS BY VERSANT CT/GC DNA 1.0**

doi:10.1136/sextrans-2013-051184.1130

<sup>1</sup>A Marangoni, <sup>1</sup>C Foschi, <sup>1</sup>P Nardini, <sup>1</sup>M Compri, <sup>2</sup>A D'Antuono, <sup>2</sup>S Bellavista, <sup>2</sup>A Filippini, <sup>3</sup>M Capretti, <sup>1</sup>R Cevenini. <sup>1</sup>University of Bologna, Microbiology, DIMES, Bologna, Italy; <sup>2</sup>University of Bologna, Dermatology, DIMES, Bologna, Italy; <sup>3</sup>S. Orsola Hospital, Neonatology, Bologna, Italy

**Objectives** Nucleic acid amplification testing (NAAT) has become the preferred method to detect *Chlamydia trachomatis* (CT) and *Neisseria gonorrhoeae* (GC) infections. Anyway, no commercial test has been cleared so far for use with extra-genital swab samples.

In this study Versant CT/GC DNA 1.0 (Siemens) performances have been evaluated by testing ocular, rectal or pharyngeal secretions collected by Siemens collection devices.

**Methods Study group.** A prospective study was performed with 7 newborns with conjunctivitis, and 183 subjects attending the STD Outpatients Clinic of St. Orsola Hospital, Bologna. The latter ones were enrolled because having unsafe receptive anal and/or pharyngeal sex intercourses.